Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis

Eriksson, Catharina; Rantapää‐Dahlqvist, Solbritt; Kg, Sundqvist

doi:10.3109/03009742.2012.754937

Cited by 26 publications

(22 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were obtained by Eriksson et al [39]. In the present study, we observed a rapid but not statistically significant short-time decrease in MCP-1 levels after a single infliximab infusion.…”

Section: Discussionsupporting

confidence: 93%

Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients

et al. 2015

View full text Add to dashboard Cite

Endothelial dysfunction can be detected by the presence of elevated levels of biomarkers of endothelial cell activation. In this study, we aimed to establish whether correlations of these biomarkers with characteristics of patients with ankylosing spondylitis (AS) exist. We also studied the effect of anti-TNF-α therapy on these biomarkers. Serum sE-selectin, MCP-1 and sVCAM-1 levels were measured by ELISA in 30 non-diabetic AS patients undergoing anti-TNF-α therapy, immediately before and after an infusion of infliximab. Correlations of these biomarkers with clinical features, systemic inflammation, metabolic syndrome and other serum and plasma biomarkers of cardiovascular risk were studied. Potential changes in the concentration of these biomarkers following an infliximab infusion were also assessed. sE-selectin showed a positive correlation with CRP (p = 0.02) and with other endothelial cell activation biomarkers such as sVCAM-1 (p = 0.019) and apelin (p = 0.008). sVCAM-1 negatively correlated with BMI (p = 0.018), diastolic blood pressure (p = 0.008) and serum glucose (p = 0.04). sVCAM-1 also showed a positive correlation with VAS spinal pain (p = 0.014) and apelin (p < 0.001). MCP-1 had a negative correlation with LDL cholesterol (p = 0.026) and ESR (p = 0.017). Patients with hip involvement and synovitis and/or enthesitis in other peripheral joints showed higher levels of MCP-1 (p = 0.004 and 0.02, respectively). A single infliximab infusion led to a significant reduction in sE-selectin (p = 0.0015) and sVCAM-1 (p = 0.04). Endothelial dysfunction correlates with inflammation and metabolic syndrome features in patients with AS. A beneficial effect of the anti-TNF-α blockade on endothelial dysfunction, manifested by a reduction in levels of biomarkers of endothelial cell activation, was observed.

show abstract

Section: Discussionsupporting

confidence: 93%

Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A recent study on IFX-treated RA patients found a greater reduction in the chemokines belonging to the Th1 than to the Th2 axis [28]. Other authors have instead observed that a 6 weeks' treatment increases the IFNγ/IL-4 ratio in IFX responders, but does not seem to affect the Th1/Th2 ratio in nonresponder patients [29].…”

Section: Discussionmentioning

confidence: 98%

Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Similarly, higher serum levels of CCL22 in patients with RA compared to healthy controls have been reported previously; however, in that study, the majority of the patients were treated with DMARD and there was no information concerning the disease duration [22]. Various treatments have been shown to affect the levels of chemokines in the circulation [15][16][17][18], which suggests that evaluation of chemokines in untreated patients might be advantageous.…”

Section: Discussionmentioning

confidence: 72%

“…Similarly, in another cohort with pre-patients and early RA patients in which blood chemokines were investigated, 39% of the patients were treated with prednisolone [14]. Treatment with biological and non-biological DMARD in RA have been shown to alter the chemokine levels in the blood [15][16][17][18], suggesting a need to evaluate chemokines in a pure group of DMARD-naive ueRA patients.…”

Section: Introductionmentioning

confidence: 99%

08.07 Blood chemokine profile in untreated early rheumatoid arthritis: cxcl10 as a disease activity marker

Pandya

Lundell

Andersson

et al. 2017

Autoimmune Inflammation

View full text Add to dashboard Cite

Background: We have recently analyzed the profile of T-cell subtypes based on chemokine receptor expression in blood from untreated early rheumatoid arthritis (ueRA) patients compared to healthy controls (HC). Here, we compared the levels of the respective chemokines in blood plasma of ueRA patients with those of HC. We also studied the association of chemokine levels with the proportions of circulating T-cell subsets and the clinical disease activity. Methods: Peripheral blood was obtained from 43 patients with ueRA satisfying the ACR 2010 criteria and who had not received any disease-modifying anti-rheumatic drugs (DMARD) or prednisolone, and from 14 sex-and age-matched HC. Proportions of T helper cells in blood, including Th0, Th1, Th2, Th17, Th1Th17, TFh, and regulatory T cells, were defined by flow cytometry. Fifteen chemokines, including several CXCL and CCL chemokines related to the T-cell subtypes as well as to other major immune cells, were measured in blood plasma using flow cytometry bead-based immunoassay or ELISA. Clinical disease activity in patients was evaluated by assessing the following parameters: Disease Activity Score in 28 joints (DAS28), Clinical Disease Activity Index (CDAI), swollen joint counts (SJC), tender joint counts (TJC), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). The data were analyzed using multivariate factor analyses followed by univariate analyses. Results: Multivariate discriminant analysis showed that patients with ueRA were separated from HC based on the blood plasma chemokine profile. The best discriminators were CXCL9, CXCL10, CXCL13, CCL4, and CCL22, which were significantly higher in ueRA compared to HC in univariate analyses. Among the chemokines analyzed, only CXCL10 correlated with multiple disease activity measures, including DAS28-CRP, DAS28-ESR, CDAI, SJC in 66 joints, CRP, and ESR.Conclusions: High circulating levels of CXCL10 in the plasma of ueRA patients and the association with the clinical disease activity suggests that CXCL10 may serve as a disease activity marker in early rheumatoid arthritis.

show abstract

Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis

Cited by 26 publications

References 37 publications

Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients

Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients

Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response

08.07 Blood chemokine profile in untreated early rheumatoid arthritis: cxcl10 as a disease activity marker

Contact Info

Product

Resources

About